Travoprost - Ocular Therapeutix
Alternative Names: Intracanalicular travoprost insert; OTX TIC; OTX-TP; OTX-TP1; OTX-TP2; OTX-TPa; OTX-TPb; PAXTRAVA; Sustained release travoprost; Travoprost implant; Travoprost insert; Travoprost intracameral implant; Travoprost ophthalmic insertLatest Information Update: 09 Apr 2024
At a glance
- Originator Ocular Therapeutix
- Class Antiglaucomas; Eye disorder therapies; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Ocular hypertension
Highest Development Phases
- Phase III Ocular hypertension; Open-angle glaucoma
- Phase II Glaucoma
Most Recent Events
- 06 Apr 2024 Ocular Therapeutix plans End-of-phase II meeting with the US FDA to discuss plans for phase III trials in Open angle glaucoma and Ocular hypertension
- 06 Apr 2024 Efficacy and adverse events data from a phase II trial in Glaucoma and Ocular hypertension released by Ocular Therapeutix
- 06 Apr 2024 Ocular Therapeutix plans phase III trials in Open angle glaucoma and Ocular hypertension (Ophthalmic)